For citations:
Shmarov M.M., Alekseeva S.V., Dovzhenko N.A., Bandelyuk A.S., Esmagambetov I.B., Shcherbinin D.N., Verkhovskaya L.V., Volchihina S.V., Simakova Ya.V., Babira V.F., Logunov D.Y., Gintsburg A.L. Safety, reactogenicity, and immunogenicity of a viral vector vaccine against influenza A: Phase I open clinical trial. Biological Products. Prevention, Diagnosis, Treatment. 2025;25(1):7-21. (In Russ.) https://doi.org/10.30895/2221-996X-2025-25-1-7-21
Email this article 